pentraxin C-reactive protein (CRP), a marker of systemic inflammation produced in hepatocytes following stimulation by cytokines, especially IL-6, have been found in MF and in patients with ET and PV. 8, 9 We tested the hypothesis that high levels of CRP could predict the progression to acute leukemia and mortality in patients with primary or post-ET/PV MF. No financial interests in connection with this work have to be declared. After IRB approval, we prospectively reviewed the medical records of 184 patients with PMF (WHO 2008 diagnosis criteria) 10 or post-ET/PV MF 11 in three Italian centers, to assess the LT rate and survival. Blood was collected during a follow-up visit or retrieved from plasma archives. A total of 78 patients (42%) received cytoreductive therapy (hydroxyurea). High-sensitivity C-reactive protein (hs-CRP) was measured as previously described. 9 Univariate comparisons were performed using the w 2 test for variables expressed as proportions and the Wilcoxon two-sample test for continuous variables. Receiver operating characteristic (ROC) analysis was used to detect the best cutoff of hs-CRP for LT prediction and death. Multivariate models were adjusted for hs-CRP levels and dynamic international prognostic scoring system (DIPSS) variables (age465 years, presence of constitutional symptoms, Hbo10 g/dl, white blood cells425 Â 10 9 /l, Accepted article preview online 5 July 2013; advance online publication, 26 July 2013 blasts41%). The ability to classify risk in individual patients was assessed by the C discrimination index introduced by Harrell et al.
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The blood levels of hs-CRP were significantly greater in patients with MF (median 5.23 mg/l, range: 0.1-130) than in 30 healthy age-adjusted controls (median 0.57 mg/l, range: 0.1-2.86) (Po0.0001). The hs-CRP blood concentration that discriminated the higher proportion of patients who developed LT and inferior survival was 7 mg/l (ROC analysis). Accordingly, clinico-hematological variables and outcomes were described in the lower and higher hs-CRP level category separately (Table 1) . Patients in the higher hs-CRP group were older (P ¼ 0.0001), had leukocytosis (425 Â 10 9 /l; P ¼ 0.010), and there was a trend for JAK2V617F homozygosity compared with heterozygosity and wild-type state (P ¼ 0.061); these patients were also more enriched in DIPSS intermediate-2 and high risk groups (Po0.0001). Median follow-up from the time of plasma collection in the two groups was 3.4 and 2.8 years, respectively. During this period, 37 leukemic transformations (20%) and 67 deaths (36%) were documented.
Patients in the higher hs-CRP level group suffered from an excess of LT events (P ¼ 0.005), corresponding to an incident rate of 2.86 (95% CI: 1.6-5.2) compared with 13.3 (95% CI: 8.4-21.2) in the higher hs-CRP level group (P ¼ 0.0001). A significantly different leukemia-free survival according to hs-CRP levels was documented by Kaplan-Meier analysis (Po0.0001) (Figure 1a) .
Hs-CRP retained the independent association with LT in multivariate analysis (P ¼ 0.015), along with age465 years (P ¼ 0.017) and peripheral blood blasts 41% (P ¼ 0.002) (Supplementary Table S1 ). The other components of DIPSS (presence of constitutional symptoms, hemoglobino10 g/dl and leukocyte count425 Â 10 9 /l) failed to show independent prognostic value to predict LT in this series of patients. Of note, DIPSS categories did not influence the independent value of hs-CRP that remained significant (P ¼ 0.05).
To each of the significant risk factors for LT, we assign an integer weight close to the corresponding HR: age 465 years: point 2, blast count 41%: point 4, hs-CRP 47 mg/l: point 2. One-hundred seventythree patients (94%), in whom all the variables were available, were divided into three categories of risk: low (sum of score: 0, n ¼ 38; 22%); intermediate (sum of score: 2-4, n ¼ 83; 48%); and high (sum of score: 6-8, n ¼ 52; 30%). Leukemia-free survival at 8 years of followup was 88% in low risk (number of events ¼ 2), 43% in intermediate risk (number of events ¼ 10) and 32% in high risk (number of events ¼ 15), respectively (P ¼ 0.0001) (Figure 1b) .
When considering the discrimination ability of DIPSS risk categories, independently of the hs-CRP values, C statistic gave a probability of concordance of 0.59 for predicting evolution in LT. Conversely, if patients were divided according to the new scoring system, which included hs-CRP, the discrimination power increased to 0.69.
The annual incidence rate of death was higher in patients with hs-CRPX7 mg/l in comparison with those o7 mg/l (19.6% patientsyear and 7.8% patients-year, respectively; P ¼ 0.0005). However, elevations of this inflammatory biomarker lost their independent significance in multivariate analysis (Supplementary Table S1 ).
To our knowledge, this is the first study exploring the relationship between the elevated blood levels of a global marker of persistent inflammation and clinically relevant events in MF. The blood elevation of hs-CRP positively correlated with survival in univariate analysis, but lost its significance in the multivariate test that included the variables of the DIPSS scoring system. Remarkably, elevated hs-CRP values were clearly associated with a higher rate of progresssion to LT both in univariate and in multivariate analysis, along with age 465 years and peripheral blasts 41%. Hs-CRP maintained its independent value when the model included the DIPSS categories. By combining hs-CRP with age and peripheral blasts, we created a score model able to discriminate patients at different risks of developing future LT.
Thus, hs-CRP might be included in the karyotype-independent model developed to predict LT in MF. 13 One is tempted to speculate that sustained inflammation may elicit the stem cell insult by inducing a state of chronic oxidative stress with elevated levels of reactive oxygen species (ROS) in the bone marrow, thereby creating a high-risk microenvironment for induction of mutations in hematopoietic cells. 14 In conclusion, we believe that our results are remarkable also considering that hs-CRP measurement is simple, cheap and available in clinical practice. Additional studies in a larger wellcharacterized patient population and external validation are needed to corroborate our findings and establish the impact of hs-CRP for the prediction of leukemic evolution. Prospectively, we suggest considering hs-CRP level as a biomarker to monitor therapy with JAK1/JAK2 inhibitors, which have been found to induce a rapid decrease of several inflammatory cytokines. Letters to the Editor
